Cover Image
市場調查報告書

帕金森氏症:開發中產品分析

Parkinson's Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229809
出版日期 內容資訊 英文 803 Pages
訂單完成後即時交付
價格
Back to Top
帕金森氏症:開發中產品分析 Parkinson's Disease - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 803 Pages
簡介

帕金森氏症,是有運動功能障礙特徵的神經退化性疾病,靜下時顫抖,肌肉僵硬,運動器官的功能障礙。原因有年齡、遺傳要素、頭部外傷、環境要素、荷爾蒙的變化等。 帕金森氏症造成神經原功能異常,也可能導致神經原死亡。神經原,擔負著信號傳達原的神經傳達物質多巴胺的合成,神經原受到影響阻礙神經有效的傳達,使運動功能和肌肉的調整力下降。

本報告提供帕金森氏症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

帕金森氏症概要

治療藥的開發

帕金森氏症:企業開發中的治療藥

帕金森氏症:大學/機關研究中的治療藥

帕金森氏症:開發中產品概況

帕金森氏症:企業開發中的產品

帕金森氏症:大學/機關研究中的產品

帕金森氏症的治療藥開發作的企業

帕金森氏症:治療藥的評估

藥物簡介

帕金森氏症:暫停中的計劃

帕金森氏症:開發中止的產品

帕金森氏症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9416IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson's disease. Parkinson's disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 32, 41, 5, 180, 48 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 1, 46, 14 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Parkinson's Disease - Overview
  • Parkinson's Disease - Therapeutics Development
  • Parkinson's Disease - Therapeutics Assessment
  • Parkinson's Disease - Companies Involved in Therapeutics Development
  • Parkinson's Disease - Drug Profiles
  • Parkinson's Disease - Dormant Projects
  • Parkinson's Disease - Discontinued Products
  • Parkinson's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Parkinson's Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H1 2017
  • Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H1 2017
  • Parkinson's Disease - Pipeline by AbbVie Inc, H1 2017
  • Parkinson's Disease - Pipeline by AC Immune SA, H1 2017
  • Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2017
  • Parkinson's Disease - Pipeline by Amabiotics SAS, H1 2017
  • Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H1 2017
  • Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Parkinson's Disease - Pipeline by Angita BV, H1 2017
  • Parkinson's Disease - Pipeline by Antoxis Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
  • Parkinson's Disease - Pipeline by APeT Holding BV, H1 2017
  • Parkinson's Disease - Pipeline by ApoPharma Inc, H1 2017
  • Parkinson's Disease - Pipeline by Aposense Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Araclon Biotech SL, H1 2017
  • Parkinson's Disease - Pipeline by ArmaGen Inc, H1 2017
  • Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Parkinson's Disease - Pipeline by Asceneuron SA, H1 2017
  • Parkinson's Disease - Pipeline by AstraZeneca Plc, H1 2017
  • Parkinson's Disease - Pipeline by Berg LLC, H1 2017
  • Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H1 2017
  • Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H1 2017
  • Parkinson's Disease - Pipeline by BioArctic AB, H1 2017
  • Parkinson's Disease - Pipeline by Biogen Inc, H1 2017
  • Parkinson's Disease - Pipeline by BioHealthonomics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Biopharm GmbH, H1 2017
  • Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Cardax Inc, H1 2017
  • Parkinson's Disease - Pipeline by Carna Biosciences Inc, H1 2017
  • Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
  • Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Clera Inc, H1 2017
  • Parkinson's Disease - Pipeline by Clevexel Pharma SAS, H1 2017
  • Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Corium International Inc, H1 2017
  • Parkinson's Disease - Pipeline by Curemark LLC, H1 2017
  • Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Easywell Biomedical Inc , H1 2017
  • Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Eli Lilly and Company, H1 2017
  • Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H1 2017
  • Parkinson's Disease - Pipeline by Evotec AG, H1 2017
  • Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Forma Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by FPRT Bio Inc, H1 2017
  • Parkinson's Disease - Pipeline by Genecode AS, H1 2017
  • Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
  • Parkinson's Disease - Pipeline by GenKyoTex SA, H1 2017
  • Parkinson's Disease - Pipeline by Genmab A/S, H1 2017
  • Parkinson's Disease - Pipeline by Genzyme Corp, H1 2017
  • Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2017
  • Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Herantis Pharma Plc, H1 2017
  • Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
  • Parkinson's Disease - Pipeline by HitGen LTD, H1 2017
  • Parkinson's Disease - Pipeline by Huons Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by ICB International Inc, H1 2017
  • Parkinson's Disease - Pipeline by Immungenetics AG, H1 2017
  • Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H1 2017
  • Parkinson's Disease - Pipeline by InnoMedica Holding AG, H1 2017
  • Parkinson's Disease - Pipeline by Intec Pharma ltd, H1 2017
  • Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2017
  • Parkinson's Disease - Pipeline by International Stem Cell Corp, H1 2017
  • Parkinson's Disease - Pipeline by Io Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Kainos Medicine Inc, H1 2017
  • Parkinson's Disease - Pipeline by Khondrion BV, H1 2017
  • Parkinson's Disease - Pipeline by KineMed Inc, H1 2017
  • Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Longevity Biotech Inc, H1 2017
  • Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H1 2017
  • Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2017
  • Parkinson's Disease - Pipeline by M's Science Corp, H1 2017
  • Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H1 2017
  • Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H1 2017
  • Parkinson's Disease - Pipeline by MedImmune LLC, H1 2017
  • Parkinson's Disease - Pipeline by Merck & Co Inc, H1 2017
  • Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017
  • Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H1 2017
  • Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Montisera Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Neonc Technologies Inc, H1 2017
  • Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H1 2017
  • Parkinson's Disease - Pipeline by Neuralstem Inc, H1 2017
  • Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
  • Parkinson's Disease - Pipeline by NeuroDerm Ltd, H1 2017
  • Parkinson's Disease - Pipeline by NeuroNascent Inc, H1 2017
  • Parkinson's Disease - Pipeline by NeurOp Inc, H1 2017
  • Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H1 2017
  • Parkinson's Disease - Pipeline by New World Laboratories Inc, H1 2017
  • Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H1 2017
  • Parkinson's Disease - Pipeline by nLife Therapeutics SL, H1 2017
  • Parkinson's Disease - Pipeline by Novartis AG, H1 2017
  • Parkinson's Disease - Pipeline by Novo Nordisk A/S, H1 2017
  • Parkinson's Disease - Pipeline by NsGene A/S (Inactive), H1 2017
  • Parkinson's Disease - Pipeline by Omeros Corp, H1 2017
  • Parkinson's Disease - Pipeline by Oncodesign SA, H1 2017
  • Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by OPKO Health Inc, H1 2017
  • Parkinson's Disease - Pipeline by Origenis GmbH, H1 2017
  • Parkinson's Disease - Pipeline by Orion Oyj, H1 2017
  • Parkinson's Disease - Pipeline by Oryzon Genomics SA, H1 2017
  • Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H1 2017
  • Parkinson's Disease - Pipeline by ParkCell AB, H1 2017
  • Parkinson's Disease - Pipeline by Parkure Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Peptron Inc, H1 2017
  • Parkinson's Disease - Pipeline by Pfizer Inc, H1 2017
  • Parkinson's Disease - Pipeline by Pharma Two B Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Pharmaxis Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Pharnext SA, H1 2017
  • Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H1 2017
  • Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H1 2017
  • Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Promius Pharma LLC, H1 2017
  • Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Prothena Corp Plc, H1 2017
  • Parkinson's Disease - Pipeline by reMYND NV, H1 2017
  • Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by SanBio Inc, H1 2017
  • Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Saniona AB, H1 2017
  • Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Shire Plc, H1 2017
  • Parkinson's Disease - Pipeline by Sigma-Tau SpA, H1 2017
  • Parkinson's Disease - Pipeline by SignPath Pharma Inc, H1 2017
  • Parkinson's Disease - Pipeline by Signum Biosciences Inc, H1 2017
  • Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by STATegics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Synthonics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Takara Bio Inc, H1 2017
  • Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2017
  • Parkinson's Disease - Pipeline by TechnoPhage SA, H1 2017
  • Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H1 2017
  • Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H1 2017
  • Parkinson's Disease - Pipeline by Trevena Inc, H1 2017
  • Parkinson's Disease - Pipeline by UCB SA, H1 2017
  • Parkinson's Disease - Pipeline by UniQure NV, H1 2017
  • Parkinson's Disease - Pipeline by Varinel Inc, H1 2017
  • Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
  • Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H1 2017
  • Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Parkinson's Disease - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Parkinson's Disease - Discontinued Products, H1 2017
  • Parkinson's Disease - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Parkinson's Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top